Johnson and Johnson 2015 Annual Report Download - page 7

mega-brands to address key consumer
need states. Our priority for this business in
2016 is to expand our market leadership in
key consumer segments in OTC, oral care,
baby products and beauty. Our health and
wellness-based products are grounded in
science and endorsed by professionals, and
we are investing in technologies that will
help us capitalize on our consumer expertise
across our broad base.
MEDICAL DEVICES
0VS.FEJDBM%FWJDFTCVTJOFTTEJEOPU
achieve its revenue ambitions for the year.
However, we did demonstrate improved
performance in several key business units
and key initiatives in 2015, including strong
operational sales growth in endocutters,
biosurgery and electrophysiology. Our priority
JO.FEJDBM%FWJDFTJTUPCFUUFSTFSWFUIF
needs of customers and patients in today’s
evolving health care marketplace. Our 2015
BDRVJTJUJPOPG$PIFSFY.FEJDBMJOUIFBSFB
of atrial fibrillation and the surgical robotics
collaboration with Verily (formerly Google
Lifesciences) are examples of the type of
strategic investments we will be focused
on in the future. As part of the restructuring
we announced in January 2016, we are also
undertaking actions to further strengthen
our go-to-market model, accelerate the pace
of innovation, prioritize key platforms and
geographies, and streamline operations while
maintaining high quality standards. We will
continue to take the bold but appropriate
TUFQTUPQVUPVS.FEJDBM%FWJDFTCVTJOFTT
in the best position to deliver more value
for customers, for our company and for
our shareholders.
market, four months ahead of schedule,
with the U.S. Food and Drug Administration
approval of DARZALEX™ (Daratumumab),
the first human monoclonal antibody to be
approved anywhere in the world for patients
with multiple myeloma. We are confident
that our above-industry investment in
R&D, demonstrated record of disciplined
acquisitions and licensing deals and strong
in-market performance, will enable us to
successfully navigate through the launches
of new competition, biosimilar and generic
entrants, and evolving market dynamics.
With the combined strength of our in-market
portfolio, deep late-stage pipeline and robust
early-stage pipeline, our objective is to
continue delivering above-industry growth.
CONSUMER
During the year, our Consumer business
exceeded operational sales goals, expanding
market share in Oral Care and U.S. OTC,
and delivering solid operational growth in
emerging markets with double-digit growth
in Brazil, India and Russia. We expect to
continue to return our Consumer business
to benchmark performance by recapturing
share, growing sales faster than competitors
and enhancing our financial metrics. In 2015,
our U.S. OTC business did just that, and we
are happy to report that nearly all of our OTC
products have returned to shelves. We are
also proud of the quality system milestones
we have completed – including receiving
OPUJDFTPGDPOGPSNJUZGPSPVS.D/FJMGBDJMJUJFT
from the U.S. Food and Drug Administration
– and the improvements we have put in
place. In Consumer, we focus our portfolio in
critical geographies and leverage our iconic
OUR GOAL IS
TO ATTRACT
& RETAIN THE
BEST TALENT
IN ORDER
TO DELIVER
THE BEST
OUTCOMES.
$)"*3."/µ4-&55&37